CJC-1295 10mg/mL

Route: Subcutaneous injection as prescribed.

• Inject subcutaneously into the abdomen, thigh, or upper arm with site rotation at each dose.
• Use aseptic technique with a new sterile syringe and needle for each injection.
• Administer on an empty stomach (≥2 hours post-meal) to minimize somatostatin-mediated GH blunting from elevated insulin.
• Inspect solution before use; do not inject if cloudy or particulate matter is visible.

There are no FDA-established dosing guidelines. The prescriber determines dose based on clinical indication and available research:

• CJC-1295 (with DAC) has been studied in humans at weekly doses of 30–90 mcg/kg, producing sustained GH and IGF-1 elevation for up to 11 days after a single dose.
• Administration frequency may be weekly or semi-weekly given the long half-life.
• The prescriber will specify dose, frequency, and duration; cycling protocols prevent pituitary desensitization.

CJC-1295: A 29-amino-acid modified GHRH peptide with a Drug Affinity Complex (DAC) that reversibly binds endogenous albumin via a reactive maleimide group, dramatically extending the biological half-life from minutes (for native GHRH) to approximately 6–8 days. Binds pituitary GHRH type 1 receptors (GHRHR), activating adenylate cyclase and increasing intracellular cAMP; this stimulates GH synthesis and secretion from somatotroph cells. A single injection produces mean GH elevations sustained over 6 days and IGF-1 elevations lasting 9–11 days in human clinical studies. Unlike direct GH administration, CJC-1295 preserves the pulsatile pattern of GH release by acting upstream at the pituitary rather than bypassing it.

CJC-1295 as a single agent provides sustained GHRH-axis stimulation with a convenient dosing frequency (potentially weekly due to the extended half-life). Clinical context includes growth hormone deficiency in adults, age-related somatotropic axis decline, and investigational use in body composition management. It differs from the CJC-1295 + ipamorelin combination by acting through only the GHRH axis, without the additional ghrelin-receptor pulsatile GH stimulus.

Prescriber monitoring:

• Serum IGF-1 monitoring is the primary surrogate marker of GH axis activity.
• Fasting glucose and insulin to assess for insulin resistance from elevated GH.
• Monitor for fluid retention, arthralgias, and carpal tunnel syndrome.
• Contraindicated in active cancer; do not use in patients with malignancy.

Contraindications:

• Active malignancy (GH/IGF-1 elevation promotes cellular proliferation)
• Hypersensitivity to CJC-1295 or formulation excipients
• Absent pituitary reserve (no functional somatotrophs to stimulate)

Warnings & Precautions:

• Not FDA-approved; human clinical data are limited to short-duration studies in healthy adults.
• Cardiovascular effects of CJC-1295 include vasodilation, flushing, and transient hypotension; the FDA has noted concerns about increased heart rate and systemic vasodilatory reactions.
• Supraphysiologic IGF-1 elevation over prolonged periods carries theoretical oncologic risk; monitor IGF-1 and titrate to physiologic range.
• Informed consent regarding investigational status is required.

Drug Interactions:

• Insulin and antidiabetic agents: GH opposes insulin action; blood glucose management may need adjustment.
• Glucocorticoids may blunt GH response to CJC-1295.
• Thyroid hormone: GH stimulates peripheral T4 → T3 conversion.

Common Side Effects: Injection site reaction, flushing, warmth, headache (transient post-injection); water retention; arthralgias; potential for insulin resistance; hypoglycemia post-peak GH (reactive hypoglycemia).

Refrigerate at 2–8°C (36–46°F). Protect from light; store in amber or opaque container. Do not freeze. Peptides are sensitive to repeated freeze-thaw cycles and thermal degradation. Bring to room temperature before administration. Use before beyond-use date assigned by Genesis Compounding.

How is single-agent CJC-1295 different from the CJC-1295 + ipamorelin combination?

CJC-1295 alone stimulates GH release exclusively through the GHRH receptor, providing sustained GH elevation. Adding ipamorelin provides a complementary ghrelin-receptor-mediated pulsatile GH stimulus. The combination produces a more physiologically complete GH secretion pattern. Single-agent CJC-1295 may be preferred when consistent sustained GH elevation (rather than pulsatile peaks) is the clinical goal.

How often do I need to inject CJC-1295?

Due to the extended half-life (~6–8 days), CJC-1295 with DAC can be administered once weekly, which is more convenient than shorter-acting GHRPs. Your prescriber will specify the exact frequency.

What is IGF-1 and why is it monitored?

Insulin-like growth factor-1 (IGF-1) is produced by the liver in response to growth hormone signaling. It mediates many of GH's anabolic effects on muscle, bone, and body composition. Serum IGF-1 is the primary laboratory measure of GH axis activity and is used to monitor CJC-1295 treatment response and ensure dosing does not produce supraphysiologic levels.

Is this product FDA-approved?

No. CJC-1295 is not FDA-approved for any indication. This is a 503A compounded sterile preparation from Genesis Compounding for a specific patient per a prescriber's order. Its use is investigational.

How should I store the vials?

Store refrigerated at 2–8°C. Protect from light and do not freeze. Bring to room temperature before injecting. Use within the labeled beyond-use date.